BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and …

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% …

PARIS, March 27, 2025 (GLOBE NEWSWIRE) -- WeRide (Nasdaq: WRD), a world leader in autonomous driving technology, announced that the company, in partnership with the leading French autonomous mobility network operator beti, has obtained France's Level-4 driverless public road testing and operating permit. This makes WeRide the first and only technology company worldwide to hold driverless permits across five countries: China, the UAE, Singapore, France, and the U.S. This remarkable milestone underscores WeRide's global leadership, demonstrating its unparalleled technological capability and adaptability to diverse regulatory frameworks, and unwavering commitment to safety, compliance, and scalability in autonomous mobility.

Lululemon earnings, US GDP forecast, and jobless claims data take center stage today, offering key insights for stock market sentiment and indices outlook.

After reaching a year-to-date (YTD) high of $5.22 on March 11 following key subsidy announcements, Nio stock (NYSE: NIO) went on to crash following a disappointing quarterly report.

MPTI, EAT and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 27, 2025.

DALLAS--(BUSINESS WIRE)--AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced that it has been selected in a joint venture by the Civil Engineering and Development Department (CEDD) of the HKSAR Government for the design and construction of Package 3 of the First Phase Development of the New Territories North – San Tin / Lok Ma Chau Development Node. This project is a cornerstone of the Northern Metropolis, a major new development in Hong Kong that will support approxima.

Specific patterns often repeat in the stock market. For example, small, unprofitable companies that surge based on hype tend to give back their gains quickly.

CVX aims to expand hydrocarbon exploration on Crete, Greece, increasing energy prospects and boosting the country's role in Mediterranean energy security.

GREENWICH, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO), a leading provider of freight transportation in North America, today announced that its Board of Directors has authorized the repurchase of up to $750 million of XPO's common stock. The new repurchase plan replaces XPO's previous share repurchase plan, authorized in February 2019, which had $503 million remaining as of March 26, 2025.

NASHVILLE, Tenn. , March 27, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today announced that it has elected to exercise its right to settle all of its prepaid stock purchase contracts, pursuant to the early settlement right in the purchase contract agreement.

NEW YORK--(BUSINESS WIRE)--New Fortress Energy Inc. (NASDAQ: NFE) (“NFE”) announced today that it has finalized a transaction with Excelerate Energy, Inc. (NYSE: EE) (“Excelerate”) to sell its assets and operations in Jamaica for $1.055 billion. Proceeds from the transaction will be used to reduce NFE's corporate debt and for general corporate purposes. This transaction is expected to close in the second quarter of 2025 and marks a key step in NFE's strategy to optimize its asset portfolio and.

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless …

BURLINGTON, Mass.--(BUSINESS WIRE)--N-able, Inc. (NYSE: NABL), a global software company helping IT services providers deliver security, data protection as-a-service, and unified endpoint management, has been recognized by CRN®, a brand of The Channel Company, with a prestigious 5-Star Award in its 2025 Partner Program Guide for the fourth consecutive year. The 5-Star Award is an elite recognition given to companies that have built their partner programs on the key elements needed to nurture la.

DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.

HONG KONG, March 27, 2025 (GLOBE NEWSWIRE) -- In the financial sector, customer demands are becoming increasingly diverse and complex. Whether it's loan inquiries, financial advice, or after-sales service, customers expect instant and accurate answers.

While the broader stock market has bounced back somewhat following its recent sell-off, many tech stocks are still well off their highs and trading at cheap valuations. Let's look at three cheap tech stocks you can buy right now.

Crude oil dips after testing 200-day MA. Traders weigh Venezuela sanctions, auto tariffs, and OPEC supply plans in shaping oil market sentiment.

Aehr Test Systems has faced significant challenges, including weak silicon carbide sales and intense competition, but remains a buy due to low valuation and potential EPS growth. Despite a sharp underperformance since early 2024 and a disappointing Q2, AEHR is diversifying revenue streams and expanding into AI processors, which could drive future growth. Key risks include ongoing supply chain issues, competition, and uncertainties in the silicon carbide market, but recent positive economic data from China offers hope for a turnaround.

NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elastic N.V. (NYSE: ESTC).